113 related articles for article (PubMed ID: 19854662)
1. Removal of TSE agents by depth or membrane filtration from plasma products.
Roberts PL; Evans D; Harris L
Biologicals; 2010 Jan; 38(1):158-61. PubMed ID: 19854662
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation.
Van Holten RW; Autenrieth SM
Vox Sang; 2003 Jul; 85(1):20-4. PubMed ID: 12823726
[TBL] [Abstract][Full Text] [Related]
3. Membrane filtration for virus removal.
Brandwein H; Aranha-Creado H
Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
[TBL] [Abstract][Full Text] [Related]
4. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products.
Foster PR; Welch AG; McLean C; Griffin BD; Hardy JC; Bartley A; MacDonald S; Bailey AC
Vox Sang; 2000; 78(2):86-95. PubMed ID: 10765143
[TBL] [Abstract][Full Text] [Related]
5. TSE clearance during plasma products separation process by Gradiflow(TM).
Wang K; Johnson A; Obradovic M; Anderson G; Maclean C; Nair H
Biologicals; 2005 Jun; 33(2):87-94. PubMed ID: 15939286
[TBL] [Abstract][Full Text] [Related]
6. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
7. Infectious prion protein in the filtrate even after 15 nm filtration.
Yunoki M; Tanaka H; Urayama T; Kanai Y; Nishida A; Yoshikawa M; Ohkubo Y; Kawabata Y; Hagiwara K; Ikuta K
Biologicals; 2010 Mar; 38(2):311-3. PubMed ID: 19931469
[TBL] [Abstract][Full Text] [Related]
8. Clearance of prions during plasma protein manufacture.
Burdick MD; Pifat DY; Petteway SR; Cai K
Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
[TBL] [Abstract][Full Text] [Related]
9. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.
Sowemimo-Coker S; Kascsak R; Kim A; Andrade F; Pesci S; Kascsak R; Meeker C; Carp R; Brown P
Transfusion; 2005 Dec; 45(12):1839-44. PubMed ID: 16371036
[TBL] [Abstract][Full Text] [Related]
10. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).
Truchot L; Arnaud T; Bloy C; Perret-Liaudet A
Biologicals; 2006 Sep; 34(3):227-31. PubMed ID: 16490361
[TBL] [Abstract][Full Text] [Related]
11. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
Kozak RW; Golker CF; Stadler P
Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
[TBL] [Abstract][Full Text] [Related]
12. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.
Neisser-Svae A; Bailey A; Gregori L; Heger A; Jordan S; Behizad M; Reichl H; Römisch J; Svae TE
Vox Sang; 2009 Oct; 97(3):226-33. PubMed ID: 19548963
[TBL] [Abstract][Full Text] [Related]
13. Removal of TSE agent from plasma products manufactured in the United Kingdom.
Roberts PL; Dalton J; Evans D; Harrison P; Li Z; Ternouth K; Thirunavukkarasu V; Bulmer M; Fernando S; McLeod N
Vox Sang; 2013 May; 104(4):299-308. PubMed ID: 23170907
[TBL] [Abstract][Full Text] [Related]
14. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter.
Van Holten RW; Autenrieth S; Boose JA; Hsieh WT; Dolan S
Transfusion; 2002 Aug; 42(8):999-1004. PubMed ID: 12385410
[TBL] [Abstract][Full Text] [Related]
15. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.
Sowemimo-Coker SO; Pesci S; Andrade F; Kim A; Kascsak RB; Kascsak RJ; Meeker C; Carp R
Vox Sang; 2006 May; 90(4):265-75. PubMed ID: 16635068
[TBL] [Abstract][Full Text] [Related]
16. Scrapie removal using Planova virus removal filters.
Tateishi J; Kitamoto T; Mohri S; Satoh S; Sato T; Shepherd A; Macnaughton MR
Biologicals; 2001 Mar; 29(1):17-25. PubMed ID: 11482889
[TBL] [Abstract][Full Text] [Related]
17. Detection of prion after decontamination procedures: comparative study of standard Western blot, filter retention and scrapie-cell assay.
Solassol J; Arlotto M; Lehmann S
J Hosp Infect; 2004 Jun; 57(2):156-61. PubMed ID: 15183247
[TBL] [Abstract][Full Text] [Related]
18. Removal of TSE agents from blood products.
Foster PR
Vox Sang; 2004 Jul; 87 Suppl 2():7-10. PubMed ID: 15209867
[No Abstract] [Full Text] [Related]
19. [Removal of human immunodeficiency virus by filtration with microporous regenerated cellulose membrane and by fractionation with polyethylene glycol].
Hamamoto Y; Yamamoto N
Nihon Rinsho; 1989 Jan; 47(1):161-7. PubMed ID: 2724562
[No Abstract] [Full Text] [Related]
20. Clearance of murine leukaemia virus from monoclonal antibody solution by a hydrophilic PVDF microporous membrane filter.
Aranha-Creado H; Peterson J; Huang PY
Biologicals; 1998 Jun; 26(2):167-72. PubMed ID: 9811524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
